Paula Ann Boriack-Sjodin

USPTO Granted Patents = 28 (Patent Applications = 14)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 5.3

ph-index = 16

Forward Citations = 587(Granted Patents)

Location History:

Waltham, MA (US) (2008 - 2012)
Lexington, MA (US) (2015 - 2021)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

where one patent can have more than one assignee

Years Active: 2008-2021

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10980794 - PRMT5 inhibitors and uses thereof (2021-04-20),

2. 10653693 - PRMT5 inhibitors and uses thereof (2020-05-19),

3. 10391089 - PRMT5 inhibitors and uses therof (2019-08-27),

4. 10307413 - Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof (2019-06-04),

5. 10227307 - PRMT1 inhibitors and uses thereof (2019-03-12),

6. 10118918 - PRMT5 inhibitors and uses thereof (2018-11-06),

7. 10039748 - PRMT1 inhibitors and uses thereof (2018-08-07),

8. 9868703 - PRMT1 inhibitors and uses thereof (2018-01-16),

9. 9776972 - Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof (2017-10-03),

10. 9765068 - PRMT5 inhibitors and uses thereof (2017-09-19),

11. 9745291 - PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof (2017-08-29),

12. 9732072 - PRMT5 inhibitors and uses thereof (2017-08-15),

13. 9732041 - Arginine methyltransferase inhibitors and uses thereof (2017-08-15),

14. 9675614 - PRMT5 inhibitors and uses thereof (2017-06-13),

15. 9604930 - Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof (2017-03-28),

Title: Paula Ann Boriack-Sjodin: Innovator in PRMT5 Inhibitors

Introduction: Paula Ann Boriack-Sjodin is a distinguished inventor based in Lexington, MA, with an impressive portfolio of 25 patents. Her groundbreaking work primarily focuses on PRMT5 inhibitors, which have significant implications in the treatment of various disorders, including cancer.

Latest Patents: Among her notable inventions are patents related to PRMT5 inhibitors and their uses. The described compounds, which include those defined by specific formulae, show promise in inhibiting PRMT5 activity. The patents outline both the compounds themselves and pharmaceutical compositions, as well as methods for their use in treating PRMT5-mediated disorders. Particularly, her techniques for utilizing these inhibitors in cancer treatment have gained recognition for their potential therapeutic applications.

Career Highlights: Paula has made substantial contributions to the pharmaceutical industry through her work with esteemed companies such as Epizyme, Inc. and GlaxoSmithKline Intellectual Property Development Limited. Her innovative mindset has facilitated advancements in drug development, particularly in the area of targeted therapies.

Collaborations: Throughout her career, Paula has collaborated with notable colleagues in the field, including Richard Chesworth and Kenneth William Duncan, further amplifying the impact of her work on PRMT5 inhibitors and their therapeutic applications.

Conclusion: Paula Ann Boriack-Sjodin exemplifies the pioneering spirit of modern inventors, with her significant contributions to the understanding and treatment of PRMT5-mediated disorders. Her continuous innovation not only enriches the scientific community but also opens new avenues for effective cancer treatments, underscoring the vital role of inventors in advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.